Liquidia Corporation — Form 8-K Summary
Business context and reporting period
Liquidia filed this Form 8-K on September 30, 2026, to report an event concerning litigation over its lead product, YUTREPIA (treprostinil) inhalation powder. This is an event filing, not a quarterly or annual financial report.
Financial and operating information
The filing text provides no revenue, profit, cash flow, margin, debt, liquidity, or other financial or operating metrics.
Material event and risks
Liquidia said it issued a press release regarding litigation filed by United Therapeutics Corporation in the U.S. District Court for the District of Delaware under the Hatch-Waxman Act. The dispute concerns U.S. Patent No. 11,826,327 and YUTREPIA. The provided filing text does not describe the press release’s substantive update, the case status, potential outcomes, or any financial impact.
Investor facts to verify
- Review Exhibit 99.1, the September 30, 2026 press release, for the litigation update and any stated implications for YUTREPIA.
- Verify the case status, relevant deadlines, and potential business or financial consequences in the underlying court filings and subsequent company disclosures.